Dermatological Consumer Products and Drugs

Galderma is dedicated to advancing dermatology through innovative technologies and research aimed at enhancing skin health. The company emphasizes a commitment to developing groundbreaking products and services that address various skin conditions across its three main areas: Aesthetics, Consumer Care, and Prescription Medicine. Their research and development pipeline is robust, featuring projects like Nemolizumab, a first-in-class monoclonal antibody targeting IL-31 to alleviate pruritus and inflammation in conditions such as atopic dermatitis. Additionally, Galderma is working on RelabotulinumtoxinA, a novel formulation of botulinum toxin designed for cosmetic applications, specifically targeting glabellar and lateral canthal lines.

Collaboration is a key aspect of Galderma's innovation strategy, as the company partners with academic and industrial entities to leverage diverse expertise and emerging technologies. This collaborative approach not only enhances their research capabilities but also allows them to better meet the needs of healthcare professionals and patients globally. Furthermore, Galderma is committed to expanding its product offerings, as seen in their ongoing development of the Cetaphil and Differin brands, ensuring they address specific skin conditions effectively. Through these initiatives, Galderma aims to make significant contributions to dermatological science and patient care.

France

Galderma is the leading company solely dedicated to skin and advancing the future of dermatology.
We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.

Galderma

Company Details